This is an aggregated industry headline. Read the full story at BioPharma Dive →
GSK shelves cough drug acquired in $2B deal
Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.
By BioPharma Dive
· Jul 17, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
From Indiana to Iceland, the FDA this week disclosed concerns raised during recent visits to a pair of manufac…
The WeekFierceBiotech ↗
After Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last …
The WeekBriefing
CMS and state actions under the American Rescue Plan Act and later legislation have made yearlong postpartum c…